Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

Lehmann, Sören, Bykov, Vladimir J.N., Ali, Dina, Andrén, Ove, Cherif, Honar, Tidefelt, Ulf, Uggla, Bertil, Yachnin, Jeffrey, Juliusson, Gunnar, Moshfegh, Ali, Paul, Christer, Wiman, Klas G., Andersson, Per-Ola·2012·Journal of Clinical Oncology

DOI 10.1200/jco.2011.40.7783

Cited by (406)

Items 201–300 of 406

Rescue of p53 functions by in vitro‐transcribed mRNA impedes the growth of high‐grade serous ovarian cancer
Monika Raab, Izabela Kostova, Samuel Peña‐Llopis, Daniela Fietz, Monika Kressin, Seyed Mohsen Aberoumandi, Evelyn Ullrich, Sven Becker, Mourad Sanhaji, Klaus Strebhardt · 2023 · 癌症：英文版
Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer
Geoffrey Bryant, Lin Wang, David J. Mulholland · 2017 · International Journal of Molecular Sciences
p53 family members — important messengers in cell death signaling in photodynamic therapy of cancer?
Pilar Acedo, Joanna Zawacka‐Pankau · 2015 · Photochemical & Photobiological Sciences
Multifunctional Compounds for Activation of the p53‐Y220C Mutant in Cancer
Jessica J. Miller, Christophe Orvain, Shireen Jozi, Ryan M. Clarke, Jason R. Smith, Anaïs Blanchet, Christian Gaiddon, Jeffrey J. Warren, Tim Storr · 2018 · Chemistry - A European Journal
Efficacy of glutathione inhibitors for the treatment of ARID1A-deficient diffuse-type gastric cancers
Mariko Sasaki, Fumiko Chiwaki, Takafumi Kuroda, Masayuki Komatsu, Keisuke Matsusaki, Takashi Kohno, Hiroki Sasaki, Hideaki Ogiwara · 2019 · Biochemical and Biophysical Research Communications
p53 biology and reactivation for improved therapy in MDS and AML
Joanna Zawacka‐Pankau · 2024 · Biomarker Research
Transcriptional Regulation by Mutant p53 and Oncogenesis
Raffaela Santoro, Sabrina Strano, Giovanni Blandino · 2014 · Sub-cellular biochemistry/Subcellular biochemistry
RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53 abnormal myeloma cells independently of the p53 pathway
Sylvanie Surget, Géraldine Descamps, Carole Brosseau, Vincent Normant, Sophie Maïga, Patricia Gomez‐Bougie, Nadège Gouy, Catherine Godon, Marie C. Béné, Philippe Moreau et al. · 2014 · BMC Cancer
PRIMA-1MET-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level
Vid Mlakar, Simona Jurković Mlakar, Laurence Lesne, Denis Marino, Komal S. Rathi, John M. Maris, Marc Ansari, Fabienne Gumy‐Pause · 2019 · Journal of Experimental & Clinical Cancer Research
The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma
Mohammad Krayem, Malak Sabbah, Ahmad Najem, An Wouters, Filip Lardon, Stephane Simon, François Salès, Fabrice Journe, Ahmad Hussein Awada, Ghanem Ghanem et al. · 2019 · Cancers
Targeting regulated cell death pathways in cancers for effective treatment: a comprehensive review
Ruchi Saxena, Craig M. Welsh, You-Wen He · 2024 · Frontiers in Cell and Developmental Biology
Pharmacological targeting of mutant p53
Samuel Kogan, Darren R. Carpizo · 2016 · Translational Cancer Research
Targeting p53 for neuroinflammation: New therapeutic strategies in ischemic stroke
Juan Gao, Jifei Liu, Yonghong Li, Junxi Liu, He Wang, Miao Chai, Ying Dong, Zhenchang Zhang, Gang Su, Manxia Wang · 2023 · Journal of Neuroscience Research
Anticancer Therapeutic Strategies Targeting p53 Aggregation
Giulia D. S. Ferretti, Julia Quarti, Gileno dos Santos, Luciana Pereira Rangel, Jerson Lima Silva · 2022 · International Journal of Molecular Sciences
PRIMA‐1 induces p53‐mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation
Haruna FURUKAWA, Tomoki Makino, Makoto Yamasaki, Koji Tanaka, Yasuhiro Miyazaki, Tsuyoshi Takahashi, Yukinori Kurokawa, Kiyokazu Nakajima, Shuji Takiguchi, Masaki Mori et al. · 2017 · Cancer Science
Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment
Michaela A. Ihle, Sebastian Huss, Wiebke Jeske, Wolfgang Hartmann, Sabine Merkelbach‐Bruse, Hans‐Ulrich Schildhaus, Reinhard Büttner, Harri J. Sihto, Kirsten Sundby Hall, Mikael Eriksson et al. · 2018 · PLoS ONE
Targeting TP53 Mutations in Myelodysplastic Syndromes
Anthony Michael Hunter, David Andrew Sallman · 2019 · Hematology/Oncology Clinics of North America
Missense mutations in the TP53 DNA-binding domain predict outcomes in patients with advanced oral cavity squamous cell carcinoma
Nina Lapke, Yen‐Jung Lu, Chun‐Ta Liao, Li‐Yu Lee, Chien‐Yu Lin, Hung‐Ming Wang, Shu‐Hang Ng, Shu‐Jen Chen, Tzu‐Chen Yen · 2016 · Oncotarget
p53: from understanding its structure to advances in therapeutic targeting
Wenhua Wang, Xia Liu, Hengqi Liu, Hassan Abolhassani, Han Yan, Huilai Zhang, Xianhuo Wang · 2026 · Signal Transduction and Targeted Therapy
BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia
Katja Seipel, Basil Kopp, Ulrike Bacher, Thomas Pabst · 2021 · Cancers
New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy
Fabio Andreozzi, Fulvio Massaro, Sébastian Wittnebel, Chloé Spilleboudt, Philippe Lewalle, Adriano Salaroli · 2022 · International Journal of Molecular Sciences
Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer
Reid Trenton Powell, Abena B. Redwood, Xuan Liu, Lei Guo, Shirong Cai, Xinhui Zhou, Yizheng Tu, Xiaomei Zhang, Yuan Qi, Yan Jiang et al. · 2020 · Scientific Reports
Strategies for p53 Activation and Targeted Inhibitors of the p53-Mdm2/MdmX Interaction
Ye Huang, Li Wang, Yuke Zhou, Jinping Bai, Ning Li, Zhengding Su, Xiyao Cheng · 2025 · Cells
Inhaled Gene Therapy in Lung Cancer: Proof-Of-Concept for Nano-Oncology and Nanobiotechnology in the Management of Lung Cancer
Paul Zarogoulidis, Kaid Darwiche, Wolfgang Hohenforst‐Schmidt, Haidong Huang, Qiang Li, Lutz Freitag, Paul Zarogoulidis · 2013 · Future Oncology
Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets
Esma Saâda-Bouzid, Christophe Le Tourneau · 2019 · Frontiers in Oncology
Abnormal accumulation of p53 predicts radioresistance leading to poor survival in patients with endometrial carcinoma
Azusa Akiyama, Takeo Minaguchi, Kaoru Fujieda, Yoshihiko Hosokawa, Keiko Nishida, Ayumi Shikama, Nobutaka Tasaka, Manabu Sakurai, Hiroyuki Ochi, Toyomi Satoh · 2019 · Oncology Letters
Noncanonical roles of p53 in cancer stemness and their implications in sarcomas
Lucie Curylova, Helena Ramos, Lucı́lia Saraiva, Jan Skoda · 2021 · Cancer Letters
P53 together with ferroptosis: a promising strategy leaving cancer cells without escape
Jianhao Zhan, Jisheng Wang, Yuqing Liang, Xiaoping Zeng, Enliang Li, Hongmei Wang · 2023 · Acta Biochimica et Biophysica Sinica
TP53 Deficiency in the Natural History of Prostate Cancer
Heidemarie Ofner, Gero Kramer, Shahrokh François Shariat, Melanie R. Hassler · 2025 · Cancers
Role of Thiol Reactivity for Targeting Mutant p53
Qiang Zhang, Jan Bergman, Klas G. Wiman, Vladimir J.N. Bykov · 2018 · Cell chemical biology
Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives
Marwan Kwok, Angelo Agathanggelou, Nicholas Davies, Tatjana Stanković · 2021 · Cancers
Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia
Jiasheng Wang, Benjamin Kent Tomlinson, Hillard Michael Lazarus · 2023 · Current Treatment Options in Oncology
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy
Seyed Esmaeil Ahmadi, Elahe Rahimian, Samira Rahimi, Bahman Zarandi, Mehran Bahraini, Maral Soleymani, Seyed Mehrab Safdari, Ashkan Shabannezhad, Niloofar Jaafari, Majid Safa · 2024 · Biomarker Research
Advances in immunotherapy and targeted therapy for pancreatic cancer
Xiangyan Zhou, Xiaohui Wang, Shengli Yang, Zaozao Huang · 2024 · Oncology and Translational Medicine
Copper-imidazo[1,2-a]pyridines induce intrinsic apoptosis and modulate the expression of mutated p53, haem-oxygenase-1 and apoptotic inhibitory proteins in HT-29 colorectal cancer cells
Leonie Harmse, Nadia Gangat, Carla Martins-Furness, Jean Dam, Charles B. de Koning · 2019 · APOPTOSIS
Interplay between HMGA and TP53 in cell cycle control along tumor progression
Nathalia Meireles Da Costa, Antônio Palumbo, Marco De Martino, Alfredo Fusco, Luís Felipe Ribeiro Pinto, Luiz Eurico Nasciutti · 2020 · Cellular and Molecular Life Sciences
Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
Ceder, Sophia, Eriksson, Sofi E., Liang, Ying Yu, Cheteh, Emarndeena H., Zhang, Si Min, Fujihara, Kenji M., Bianchi, Julie, Bykov, Vladimir J. N., Abrahmsen, Lars, Clemons, Nicholas J. et al. · 2021 · Cell Death & Disease
Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients
Yoshimitsu Shimomura, Masahiko Hara, Takaaki Konuma, Hidehiro Itonaga, Noriko Doki, Yukiyasu Ozawa, Tetsuya Eto, Naoyuki Uchida, Jun Aoki, Jun Kato et al. · 2021 · Bone Marrow Transplantation
Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors
Anna Thulin, Carola Andersson, Elisabeth Werner Rönnerman, Shahin De Lara, Chaido Chamalidou, Arnd Schoenfeld, Anikó Kovács, Henrik Fagman, Fredrik Enlund, Barbro Kristina Linderholm · 2021 · Scientific Reports
Tumor profiling of gastric and esophageal carcinoma reveal different treatment options
John Thomas Miura, Joanne Xiu, James Phillip Thomas, Ben George, Benjamin R Carron, Susan Tsai, Fabian Mc. Johnston, Kiran Kalyan Turaga, Thomas Clark Gamblin · 2015 · Cancer Biology & Therapy
Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials
Stephen Anthony Strickland, Zhuoxin Sun, Rhett P. Ketterling, Athena M. Cherry, Larry Dean Cripe, Gordon W. Dewald, Hugo Francisco Fernandez, Gary A. Hicks, Rodney R. Higgins, Hillard Michael Lazarus et al. · 2017 · Leukemia Research
Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment
Elizabeth A. Lopes, Sara Gomes, Lucı́lia Saraiva, Maria M. M. Santos · 2018 · Current Medicinal Chemistry
From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia
Carmelo Gurnari, Maria Teresa Voso, Jaroslaw Pawel Maciejewski, Valeria Visconte · 2020 · Cancers
Redefining Therapeutic Approaches in Colorectal Cancer: Targeting Molecular Pathways and Overcoming Resistance
Simona Gabriela Duta-Ion, Ioana Ruxandra Juganaru, Iulian Andrei Hotinceanu, Andra Dan, Livia Mălina Burtavel, Madalin Codrut Coman, Ina Ofelia Focșa, Andra-Giorgiana Zaruha, Patricia Christina Codreanu, Laurențiu Camil Bohîlțea et al. · 2024 · International Journal of Molecular Sciences
MDM2 oligomers: antagonizers of the guardian of the genome
Patrick L. Leslie, Yingao Zhang · 2016 · Oncogene
APR-246/PRIMA-1 Met Inhibits and Reverses Squamous Metaplasia in Human Conjunctival Epithelium
Jing Li, Cheng Li, Guoliang Wang, Zhen Liu, Pei Chen, Qichen Yang, Nuo Dong, Huping Wu, Zuguo Liu, Wei Shan Li · 2016 · Investigative Ophthalmology & Visual Science
The Relationship betweenTP53Gene Status and Carboxylesterase 2 Expression in Human Colorectal Cancer
Momoko Ishimine, Hyeon‐Cheol Lee, Hirofumi Nakaoka, Hajime Orita, Toshiyuki Kobayashi, Konomi Mizuguchi, Mikumi Endo, Ituro Inoue, Koichi Sato, Takehiko Yokomizo · 2018 · Disease Markers
Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer
Jørgen Smeby, Anita Sveen, Christian Holst Bergsland, Ina Andrassy Eilertsen, Stine Aske Danielsen, Peter W. Eide, Merete Hektoen, Marianne G. Guren, Arild Nesbakken, Jarle Bruun et al. · 2019 · ESMO Open
The predictive capability of immunohistochemistry and DNA sequencing for determining TP53 functional mutation status: a comparative study of 41 glioblastoma patients
Aarash K. Roshandel, Christopher M. Busch, Jennifer Van Mullekom, Joshua A. Cuoco, Cara Marie Rogers, Lisa S. Apfel, Eric A. Marvin, Harald W. Sontheimer, Robyn A. Umans · 2019 · Oncotarget
A molecular dynamics and docking study to screen anti-cancer compounds targeting mutated p53
Hetal Damani Shah, Dhananjaya Saranath, Vinuthaa Murthy · 2020 · Journal of Biomolecular Structure and Dynamics
TP53in adult acute lymphoblastic leukemia
Silvia Salmoiraghi, Alessandro Rambaldi, Orietta Spinelli · 2017 · Leukemia & lymphoma/Leukemia and lymphoma
Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma
Yan Li, Zhengang Zhao, Yin Luo, Hao Cui, Hao-Yu Wang, Yan-Fang Jia, Ying-Tang Gao · 2020 · World Journal of Gastroenterology
Progress in deciphering the role of p53 in diffuse large B-cell lymphoma: mechanisms and therapeutic targets
Wen Wen · 2024 · American Journal of Cancer Research
Updates on the Management of Acute Myeloid Leukemia
Sofía Huerga-Domínguez, Sara Villar, Felipe Prósper, Ana Alfonso Piérola · 2022 · Cancers
Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC ‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
Davidson Zhao, Entsar Eladl, Mojgan Zarif, José‐Mario Capo‐Chichi, Andre C. Schuh, Eshetu G. Atenafu, Mark David Minden, Hong Chang · 2022 · Cancer Medicine
TP53 and therapy-related myeloid neoplasms
Jae Chung, David Andrew Sallman, Eric Padron · 2019 · Best Practice & Research Clinical Haematology
Identification of Acute Pancreatitis-Related Genes and Pathways by Integrated Bioinformatics Analysis
Liya Fan, Xiaoliang Hui, Ying Qing Mao, Jun Liang Zhou · 2019 · Digestive Diseases and Sciences
Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response
Elisena Franzese, Sara Centonze, Anna Diana, Angela Lombardi, Francesca Carlino, Luigi Pio Guerrera, Ferdinando De Vita, Michele Caraglia, Sandro Pignata, Fortunato Ciardiello et al. · 2019 · Frontiers in Oncology
APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells
Javier de la Rosa, Alejandro Urdiciain, María Victoria Zelaya, Idoya Zazpe, Bárbara Meléndez, JUAN ANTONIO REY, Miguel Angel Idoate, Javier S. Castresana · 2021 · International Journal of Oncology
Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches
Nicole Renee Grieselhuber, Alice S. Mims · 2021 · Current Hematologic Malignancy Reports
Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue
Brad D. Wallentine, Ying Wang, Vira Tretyachenko-Ladokhina, Martha Tan, Donald F. Senear, Hartmut Luecke · 2013 · Acta Crystallographica Section D Biological Crystallography
TP 53 mutations and MDM2SNP309 identify subgroups of AML patients with impaired outcome
Ingrid Jakobsen Falk, Kerstin Willander, Roza Chaireti, Johan Lund, Hareth Nahi, Monica Hermanson, Henrik Gréen, Kourosh Lotfi, Peter Söderkvist · 2014 · European Journal Of Haematology
The molecular mechanism of action of methylene quinuclidinone and its effects on the structure of p53 mutants
Sara Ibrahim Omar, Jack A. Tuszyński · 2018 · Oncotarget
APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
Xuqin Xie, Chuanwen Fan, Bin Luo, Jing Zhang, Lasse D. Jensen, Jonas Burman, Carolin Jönsson, Anna Ljusberg, Peter Larsson, Zengren Zhao et al. · 2023 · Molecular Cancer Therapeutics
Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer
Furong Huang, Kexin Li, Jeffrey W. Shevach, Qianben Wang · 2025 · Journal of the National Cancer Center
AI-powered discovery of a novel p53-Y220C reactivator
Shan Zhou, Dafei Chai, Xu Wang, Praveen Kumar Neeli, Xinfang Yu, Aram Davtyan, Ken H. Young, Yong Li · 2023 · Frontiers in Oncology
Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma
Michael Müller, Lisa Rösch, Sara Najafi, Charlotte Gatzweiler, Johannes Ridinger, Xenia F. Gerloff, David Jones, Jochen Baßler, Sina Kreth, Sabine A. Stainczyk et al. · 2021 · Cancers
Multiparametric Circulating Tumor Cell Analysis to Select Targeted Therapies for Breast Cancer Patients
André Franken, Bianca Behrens, Florian Reinhardt, Liwen Yang, Mahdi Rivandi, Francesco Marass, Bernadette AS Jaeger, Natalia Krawczyk, Jan‐Philipp Cieslik, Ellen Honisch et al. · 2021 · Cancers
Establishment and validation of a carbohydrate metabolism-related gene signature for prognostic model and immune response in acute myeloid leukemia
You Bing Yang, Yan Yang, Jing L. Liu, Yan Zeng, Qulian Guo, Jing Guo, Ling Guo, Haiquan Lu, Wenjun Liu · 2022 · Frontiers in Immunology
An expert overview of emerging therapies for acute myeloid leukemia: novel small molecules targeting apoptosis, p53, transcriptional regulation and metabolism
Kapil Saxena, Marina Y Konopleva · 2020 · Expert Opinion on Investigational Drugs
Getting personal with myelodysplastic syndromes: is now the right time?
Nora Chokr, Alexander B. Pine, Jan Philipp Bewersdorf, Rory Michael Shallis, Maximilian F. Stahl, Amer Methqal Zeidan · 2019 · Expert Review of Hematology
How Driver Oncogenes Shape and Are Shaped by Alternative Splicing Mechanisms in Tumors
Weronika Wojtyś, Magdalena Oroń · 2023 · Cancers
The p53 reactivator PRIMA-1MET synergises with 5-fluorouracil to induce apoptosis in pancreatic cancer cells
Ibtehal Mohammed, Ali Haider Alhammer, Inam Sameh Arif · 2023 · Investigational New Drugs
Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches
Karanpreet Singh Bhatia, Vedant Sandhu, Mei Hsuan Wong, Prasad Iyer, Shruti Bhatt · 2024 · Frontiers in Oncology
Prognostic Significance of TP53 Mutations and Single Nucleotide Polymorphisms in Acute Myeloid Leukemia: A case Series and Literature Review
Simon Blechman Zeichner, Sarah Alghamdi, Gina Elhammady, Robert Poppiti, Amilcar Antonio Castellano-Sanchez · 2014 · Asian Pacific Journal of Cancer Prevention
Phase Separation and Prion‐Like Aggregation of p53 Family Tumor Suppressors: From Protein Evolution to Cancer Treatment
Jerson Lima Silva, Guilherme Caldas de Andrade, Elaine C. Petronilho, Gileno dos S. de Sousa, Michelle F. Mota, Julia Quarti, Francisca Hildemagna Guedes-da-Silva, Giulia D. S. Ferretti, Luciana Pereira Rangel, Tuane C. R. G. Vieira et al. · 2025 · Journal of Neurochemistry
The Discovery of Cryptic Pockets Increases the Druggability of “Undruggable” Proteins
Mingyue Mou, Wei‐Cheng Yang, Guangyi Huang, Xiaoyan Yang, Xiao Li Zhang, Wishwajith Kandegama, Charles R. Ashby, Ge‐Fei Hao, Yangyang Gao · 2025 · Medicinal Research Reviews
Anticancer therapeutic strategies for targeting mutant p53-Y220C
Vitaly V. Chasov, Damir Davletshin, Elvina Gilyazova, Regina Mirgayazova, Anna A. Kudriaeva, Raniya Khadiullina, Youyong Yuan, Emil Bulatov · 2023 · Journal of Biomedical Research
APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice
Yayun Liang, Cynthia L Besch-Williford, Matthew T. Cook, Anthony M. Belenchia, Rolf A. Brekken, Salman M. Hyder · 2019 · Breast Cancer Targets and Therapy
Comprehensive omics studies of p53 mutants in human cancer
Lakshay Malhotra, Alankrita Singh, Punit Kaur, Abdul Samath Ethayathulla · 2022 · Briefings in Functional Genomics
Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect
H. Moses Murdock, Vincent T. Ho, Jacqueline Suen Garcia · 2024 · Frontiers in Immunology
SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes
David Andrew Sallman, Tiffany N. Tanaka, Alan F. List, Rafael L. Bejar · 2017 · Clinical Lymphoma Myeloma & Leukemia
The p53 inhibitor, pifithrin-α, disrupts microtubule organization, arrests growth, and induces polyploidy in the rainbow trout gill cell line, RTgill-W1
Fanxing Zeng, Xiang Yu, James P. Sherry, Brian Dixon, Bernard P. Duncker, Niels C. Bols · 2015 · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology
Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals
Saverio Candido, Stephen Lee Abrams, Linda S. Steelman, Kvin Lertpiriyapong, Alberto Maria Martelli, Lucio Cocco, Stefano Ratti, Matilde Y. Follo, Ramiro Mendonça Murata, Pedro Luiz Rosalen et al. · 2019 · Advances in Biological Regulation
Restoring guardianship of the genome: Anticancer drug strategies to reverse oncogenic mutant p53 misfolding
Husam A. Babikir, Rayhaneh Afjei, Ramasamy Paulmurugan, Tarik F. Massoud · 2018 · Cancer Treatment Reviews
Genome‑wide ChIP‑seq data with a transcriptome analysis reveals the groups of genes regulated by histone demethylase LSD1 inhibition in esophageal squamous cell carcinoma cells
Isamu Hoshino, Masahīko Takahashi, Yasunori Akutsu, Kentaro Murakami, Yasunori Matsumoto, Hiroshi Suito, Nobufumi Sekino, Aki Komatsu, Keiko Iida, Takayoshi Suzuki et al. · 2019 · Oncology Letters
The clinical development of p53-reactivating drugs in sarcomas – charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins
Swethajit Biswas, Emma Killick, Aart G. Jochemsen, John Lunec · 2014 · Expert Opinion on Investigational Drugs
Key genes altered in glioblastoma based on bioinformatics (Review)
Marcelino Al Ghafari, Nour El Jaafari, Mariam Mouallem, Tala Maassarani, Mirvat El‐Sibai, Ralph Joseph Abi‐Habib · 2025 · Oncology Letters
Decoding the Pathophysiology and the Genetics of Multiple Myeloma to Identify New Therapeutic Targets
Panisinee Lawasut, Richard W.J. Groen, Eugen Dhimolea, Paul Gerard Guy Richardson, Kenneth Carl Anderson, Constantine S. Mitsiades · 2013 · Seminars in Oncology
DNA-delivered monoclonal antibodies targeting the p53 R175H mutant epitope inhibit tumor development in mice
Dafei Chai, Xu Wang, Praveen Kumar Neeli, Shan Zhou, Xingfang Yu, Kanaga Sabapathy, Yong Li · 2023 · Genes & Diseases
Virtual screening using covalent docking to find activators for G245S mutant p53
Sara Ibrahim Omar, Marco Gaetano Lepre, Umberto Morbiducci, Marco A. Deriu, Jack A. Tuszyński · 2018 · PLoS ONE
Synergistic and additive effect of retinoic acid in circumventing resistance to p53 restoration
Connie A. Larsson, Sydney M. Moyer, Bin Liu, Keith A. Michel, Vinod Pant, Peirong Yang, Justin Wong, Adel K. El‐Naggar, Ralf Krahe, Guillermina Lozano · 2018 · Proceedings of the National Academy of Sciences
RITA requires eIF2α-dependent modulation of mRNA translation for its anti-cancer activity
Johannes Ristau, Vincent van Hoef, Sylvain Peuget, Jiawei Zhu, Bo‐Jhih Guan, Shuo Liang, Maria Hatzoglou, Ivan Topisirović, Galina Selivanova, Ola Segnestam Larsson · 2019 · Cell Death and Disease
Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status
Javier Octavio Mejía-Hernández, Dinesh Raghu, Franco Caramia, Nicholas James Clemons, Kenji Mark Fujihara, Thomas Riseborough, Amina F.A.S. Teunisse, Aart G. Jochemsen, Lars Abrahmsén, Giovanni Blandino et al. · 2022 · Cancers
PRIMA-1MET cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cells
Zuzana Jašková, Šárka Pavlová, Jitka Malčíková, Yvona Brychtová, Martin Trbušek · 2019 · Leukemia Research
APR-246—The Mutant TP53 Reactivator—Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells
James Andrew McCubrey, Stephen Lee Abrams, Linda S. Steelman, Lucio Cocco, Stefano Ratti, Alberto Maria Martelli, Paolo Lombardi, Agnieszka Gizak, Przemysław Duda · 2022 · Biomolecules
Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach
Verónica González‐Calle, Niamh Keane, Esteban Braggio, Rafaël Fonseca · 2017 · Clinical Lymphoma Myeloma & Leukemia
Treatments targeting MDS genetics: a fool’s errand?
Amy Elizabeth Dezern · 2018 · Hematology
Prima-1 and APR-246 in Cancer Therapy
Pavlína Zatloukalová, Michaela Galoczová, Bořivoj Vojtěšek · 2018 · Klinicka onkologie
Genomic landscape of biliary tract cancer and corresponding targeted treatment strategies
Daisaku Yamada, Shogo Kobayashi, Yuichiro Doki, Hidetoshi Eguchi · 2025 · International Journal of Clinical Oncology